ICON Public (ICLR) to Release Quarterly Earnings on Wednesday

ICON Public (NASDAQ:ICLR) is set to issue its quarterly earnings data after the market closes on Wednesday, October 23rd. Analysts expect the company to announce earnings of $3.72 per share for the quarter. ICON Public has set its FY24 guidance at $15.00-$15.20 EPS.Parties interested in registering for the company’s conference call can do so using this link.

ICON Public (NASDAQ:ICLR) last issued its earnings results on Wednesday, July 24th. The medical research company reported $3.75 earnings per share for the quarter, topping analysts’ consensus estimates of $3.68 by $0.07. The business had revenue of $2.10 billion during the quarter, compared to the consensus estimate of $2.14 billion. ICON Public had a return on equity of 12.06% and a net margin of 8.57%. The firm’s revenue for the quarter was up 4.1% on a year-over-year basis. During the same period in the previous year, the company posted $2.96 earnings per share. On average, analysts expect ICON Public to post $15 EPS for the current fiscal year and $17 EPS for the next fiscal year.

ICON Public Trading Up 0.8 %

Shares of ICLR stock opened at $297.72 on Monday. The company has a market cap of $24.56 billion, a P/E ratio of 36.22, a PEG ratio of 1.35 and a beta of 1.22. The stock has a 50 day simple moving average of $303.72 and a two-hundred day simple moving average of $312.29. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.31 and a current ratio of 1.31. ICON Public has a fifty-two week low of $221.20 and a fifty-two week high of $347.72.

Analyst Upgrades and Downgrades

ICLR has been the subject of a number of research analyst reports. Evercore ISI lowered their target price on ICON Public from $360.00 to $350.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. StockNews.com downgraded ICON Public from a “buy” rating to a “hold” rating in a report on Thursday, September 19th. Truist Financial decreased their price objective on ICON Public from $383.00 to $363.00 and set a “buy” rating for the company in a report on Monday, October 14th. Robert W. Baird decreased their price objective on ICON Public from $368.00 to $340.00 and set an “outperform” rating for the company in a report on Friday, September 20th. Finally, Leerink Partners initiated coverage on ICON Public in a report on Wednesday, September 18th. They set an “outperform” rating and a $379.00 price objective for the company. Two research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, ICON Public presently has a consensus rating of “Moderate Buy” and an average price target of $346.09.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.